ReviewDiscover oncology2025
Targeted drug monitoring in oncology for personalized treatment with use of next generation analytics.
Review in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Metronomic Chemotherapy in Ovarian Cancer: Current Scenario and AI-Integrated Future Strategies.Cancer reports (Hoboken, N.J.) · 2026Review
- Different chromatographic techniques and recent advancements for biomedical and pharmaceutical applications.Northern clinics of Istanbul · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Therapeutic drug monitoring (TDM) is a clinical procedure aimed at maintaining plasma drug concentrations within a specific therapeutic range, thereby maximizing the safety and efficacy of pharmacological therapy. Conventional oncology strategies face challenges like non-specific toxicity, drug resistance, incomplete tumor eradication, high costs, and significant side effects that impact quality of life. Moreover, conventional therapy offers limited benefits in advanced stages, pose risks of secondary cancers and immune suppression, and lack personalization, highlighting the need for targeted, innovative approaches. In modern oncology, TDM has gained significant interest due to narrow therapeutic windows, significant inter-individual variability in pharmacokinetics, and the complexity of cancer pharmacotherapy. This study reviews the role of TDM in oncology with more emphasis on pharmacogenetic testing, immunoassays, and liquid-chromatography-mass spectroscopy (LC-MS/MS) techniques, highlighting its applications in optimizing the dose during immunotherapies, targeted therapies, and chemotherapeutics. Moreover, the review discusses the challenges and limitations associated with TDM in oncology, such as the requirement of robust clinical evidence, standardized practices, and integration with personalized medicine approaches. Emerging technologies, including AI and machine learning, are also considered for their potential to enhance TDM in oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.